NAGIOS: RODERIC FUNCIONANDO

The timing of introduction of pharmaceutical innovations in seven European countries

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

The timing of introduction of pharmaceutical innovations in seven European countries

dc.contributor.author	Westerling, Ragnar	es_ES
dc.contributor.author	Westin, Marcus	es_ES
dc.contributor.author	McKee, Martin	es_ES
dc.contributor.author	Hoffmann, Rasmus	es_ES
dc.contributor.author	Plug, Iris	es_ES
dc.contributor.author	Rey, Grégoire	es_ES
dc.contributor.author	Jougla, Eric	es_ES
dc.contributor.author	Lang, Katrin	es_ES
dc.contributor.author	Pärna, Kersti	es_ES
dc.contributor.author	Alfonso Sánchez, José Luis	es_ES
dc.contributor.author	Mackenbach, Johan P.	es_ES
dc.date.accessioned	2015-06-10T08:35:42Z
dc.date.available	2015-06-10T08:35:42Z
dc.date.issued	2014	es_ES
dc.identifier.citation	Journal of Evaluation in Clinical Practice Vol. 20 Issue 4: pp. 301-310	es_ES
dc.identifier.uri	http://hdl.handle.net/10550/44276
dc.description.abstract	Rationale, aims and objectivesDifferences in the performance of medical care may be due to variation in the introduction and diffusion of medical innovations. The objective of this paper is to compare seven European countries (United Kingdom, the Netherlands, West Germany, France, Spain, Estonia and Sweden) with regard to the year of introduction of six specific pharmaceutical innovations (antiretroviral drugs, cimetidine, tamoxifen, cisplatin, oxalaplatin and cyclosporin) that may have had important population health impacts.MethodsWe collected information on introduction and further diffusion of drugs using searches in the national and international literature, and questionnaires to national informants. We combined various sources of information, both official years of registration and other indicators of introduction (clinical trials, guidelines, evaluation reports, sales statistics).Results and conclusionsThe total length of the period between first and last introduction varied between 8 years for antiretroviral drugs and 22 years for cisplatin. Introduction in Estonia was generally delayed until the 1990s. The average time lags were smallest in France (2.2 years), United Kingdom (2.8 years) and the Netherlands (3.5 years). Similar rank orders were seen for year of registration suggesting that introduction lags are not only explained by differences in the process of registration. We discuss possible reasons for these between-country differences and implications for the evaluation of medical care.	es_ES
dc.subject	health systems	es_ES
dc.subject	medical care	es_ES
dc.subject	mortality	es_ES
dc.subject	outcome measures	es_ES
dc.subject	pharmaceuticals	es_ES
dc.subject	quality of care	es_ES
dc.title	The timing of introduction of pharmaceutical innovations in seven European countries	es_ES
dc.type	journal article	es_ES
dc.identifier.doi	10.1111/jep.12122	es_ES
dc.identifier.idgrec	097261	es_ES